| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Article |
1 Department of Surgical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, 301 Groene Hilledijk, 3075 EA Rotterdam, The Netherlands
2 Department of Statistics, Erasmus MC-Daniel den Hoed Cancer Center, 301 Groene Hilledijk, 3075 EA Rotterdam, The Netherlands
Correspondence: Address correspondence and reprint requests to: Alexander M. M. Eggermont, MD, PhD; E-mail: a.m.m.eggermont{at}erasmusmc.nl
Background: Treatment for extremity soft tissue sarcoma (STS) has shifted in recent years from amputation to local wide excision combined with irradiation. For multiple sarcomas, this limb-sparing approach is often not possible. To avoid amputations, isolated limb perfusion (ILP) with tumor necrosis factor and melphalan is an attractive treatment option for patients with multiple extremity sarcomas.
Methods: We investigated a prospective database at a tertiary referral institute. From July 1991 to July 2003, out of 217 ILPs, 64 ILPs were performed for either multifocal primary sarcomas or multiple sarcoma recurrences in 53 patients. All ILPs were performed under mild hyperthermic conditions by using 1 to 4 mg of tumor necrosis factor and 10 to 13 mg/L of limb volume for leg and arm perfusions, respectively.
Results: The overall response was 88%, with 42% complete response, 45% partial response, 11% no change, and 2% progressive disease. This response rate is significantly better than our experience in 153 locally advanced single-STS cases (88% vs. 69%). The toxicity of the procedure was mild to moderate in almost all cases; no treatment-related amputation had to be performed. The time to local recurrence was 29 months and differed significantly between multiple primary and multiple recurrent STS. The 5-year survival rate was 39%. Limb salvage was achieved in 45 (82%) of 55 treated limbs.
Conclusions: In a group of patients who are uniformly candidates for amputation, ILP can achieve limb salvage in approximately four out of five patients. Because this treatment option provides excellent local control, it should be considered before an amputation is planned.
Key Words: Isolated limb perfusion • Soft tissue sarcoma • Extremity • TNF
This article has been cited by other articles:
 |
|
 |
|
  M. L. Hoven-Gondrie, K. M. J. Thijssens, J. H. B. Geertzen, E. Pras, R. J. van Ginkel, and H. J. Hoekstra Isolated Limb Perfusion and External Beam Radiotherapy for Soft Tissue Sarcomas of the Extremity: Long-Term Effects on Normal Tissue According to the LENT-SOMA Scoring System Ann. Surg. Oncol., May 1, 2008; 15(5): 1502 - 1510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Hohenberger and W. M. Wysocki Neoadjuvant Treatment of Locally Advanced Soft Tissue Sarcoma of the Limbs: Which Treatment to Choose? Oncologist, February 1, 2008; 13(2): 175 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Pennacchioli, M. Deraco, L. Mariani, M. Fiore, C. Mussi, P. Collini, P. Olmi, P. G. Casali, M. Santinami, and A. Gronchi Advanced Extremity Soft Tissue Sarcoma: Prognostic Effect of Isolated Limb Perfusion in a Series of 88 Patients Treated at a Single Institution Ann. Surg. Oncol., February 1, 2007; 14(2): 553 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. van Horssen, T. L. M. ten Hagen, and A. M. M. Eggermont TNF-{alpha} in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility. Oncologist, April 1, 2006; 11(4): 397 - 408. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
